Membrane-bound complement regulatory proteins inhibit complement activation by an immunotherapeutic mAb in a syngeneic rat colorectal cancer model

Molecular Immunology

Volumn 40, Issue 1, 2003, Pages 13-23

  Gelderman, K A ^a   Hakulinen, J ^b   Hagenaars, M ^a   Kuppen, P J K ^a   Meri, S ^b   Gorter, A ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF HELSINKI   (Finland)

Author keywords

CC531; CD55; CD59; Colon carcinoma; Complement; Crry p65; Immunotherapy; Rat

Indexed keywords

CD59 ANTIGEN; COMPLEMENT; IMMUNOGLOBULIN G2A; IMMUNOGLOBULIN G3; MEMBRANE BOUND COMPLEMENT REGULATORY PROTEIN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY MG 1; MONOCLONAL ANTIBODY MG 2; MONOCLONAL ANTIBODY MG 3; MONOCLONAL ANTIBODY MG 4 2A; REGULATOR PROTEIN; SYNAPTOTAGMIN; TUMOR ASSOCIATED MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CANCER MODEL; COLORECTAL CARCINOMA; COMPLEMENT ACTIVATION; COMPLEMENT DEPOSITION; COMPLEMENT INHIBITION; CONTROLLED STUDY; CYTOLYSIS; DRUG EFFECT; IMMUNOTHERAPY; IN VITRO STUDY; IN VIVO STUDY; INHIBITION KINETICS; INJECTION; ISOGRAFT; LIVER; MALE; METASTASIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; RAT; SCAPULA; SOLID TUMOR; TISSUE SECTION;

ANIMALIA;

EID: 0043198230     PISSN: 01615890     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0161-5890(03)00048-8     Document Type: Article

References (42)

1. Baranyi L., Baranji K., Takizawa H., Okada N., Okada H. Cell-surface bound complement regulatory activity is necessary for the in vivo survival of KDH-8 rat hepatoma. Immunology. 82:1994;522-528.
2. Bergman I., Arbit E., Rosenblum M., Larson S.M., Heller G., Cheung N.K. Treatment of spinal epidural neuroblastoma xenografts in rats using anti-GD2 monoclonal antibody 3F8. J. Neurooncol. 15:1993;235-242.
3. Bonsing B.A., Corver W.E., Gorsira M.C., van Vliet M., Oud P.S., Cornelisse C.J., Fleuren G.J. Specificity of seven monoclonal antibodies against p53 evaluated with Western blotting, immunohistochemistry, confocal laser scanning microscopy, and flow cytometry. Cytometry. 28:1997;11-24.
4. Boot J.H., Geerts M.E., De Groot E.R., Aarden L.A. Murine monoclonal isotype switch variants. Detection with rat monoclonal antibodies in ELISA and isolation by sequential sublining. J. Immunol. Methods. 106:1988;195-202.
5. Caragine T.A., Okada N., Frey A.B., Tomlinson S. A tumor-expressed inhibitor of the early but not late complement lytic pathway enhances tumor growth in a rat model of human breast cancer. Cancer Res. 62:2002;1110-1115.
6. Clark M. Antibody humanization: a case of the 'Emperor's new clothes'? Immunol. Today. 21:2000;397-402.
7. Gelderman K.A., Blok V.T., Fleuren G.J., Gorter A. The inhibitory effect of CD46, CD55, and CD59 on complement activation after immunotherapeutic treatment of cervical carcinoma cells with monoclonal antibodies or bispecific monoclonal antibodies. Lab. Invest. 82:2002a;483-493.
8. Gelderman K.A., Kuppen P.J., Bruin W., Fleuren G.J., Gorter A. Enhancement of the complement activating capacity of 17-1A mAb to overcome the effect of membrane-bound complement regulatory proteins on colorectal carcinoma. Eur. J. Immunol. 32:2002b;128-135.
9. Gorter A., Meri S. Immune evasion of tumor cells using membrane-bound complement regulatory proteins. Immunol. Today. 20:1999;576-582.
10. Hagenaars M., Koelemij R., Ensink N.G., van Eendenburg J.D., van Vlierberghe R.L., Eggermont A.M., van de Velde C.J., Fleuren G.J., Kuppen P.J. The development of novel mouse monoclonal antibodies against the CC531 rat colon adenocarcinoma. Clin. Exp. Metastasis. 18:2000;281-289.
11. Harris C.L., Spiller O.B., Morgan B.P. Human and rodent decay-accelerating factors (CD55) are not species restricted in their complement-inhibiting activities. Immunology. 100:2000;462-470.
12. Hinchliffe S.J., Spiller O.B., Rushmere N.K., Morgan B.P. Molecular cloning and functional characterization of the rat analogue of human decay-accelerating factor (CD55). J. Immunol. 161:1998;5695-5703.
13. Hughes T.R., Piddlesden S.J., Williams J.D., Harrison R.A., Morgan B.P. Isolation and characterization of a membrane protein from rat erythrocytes which inhibits lysis by the membrane attack complex of rat complement. Biochem. J. 284:1992;169-176.
14. Juhl H., Petrella E.C., Cheung N.K., Bredehorst R., Vogel C.W. Additive cytotoxicity of different monoclonal antibody-cobra venom factor conjugates for human neuroblastoma cells. Immunobiology. 197:1997;444-459.
15. Junnikkala S., Hakulinen J., Meri S. Targeted neutralization of the complement membrane attack complex inhibitor CD59 on the surface of human melanoma cells. Eur. J. Immunol. 24:1994;611-615.
16. Kanazawa J., Ohta S., Shitara K., Fujita F., Fujita M., Hanai N., Akinaga S., Okabe M. Therapeutic potential of chimeric anti-(ganglioside GD3) antibody KM871: antitumor activity in xenograft model of melanoma and effector function analysis. Cancer Immunol. Immunother. 49:2000;253-258.
17. Koretz K., Brüderlein S., Henne C., Möller P. Decay-accelerating factor (DAF, CD55) in normal colorectal mucosa, adenomas and carcinomas. Br. J. Cancer. 66:1992;810-814.
18. Kroesen B.J., McLaughlin P.M., Schuilenga-Hut P.H., Jacobs S.C., Molema G., Helfrich W., de Leij L.F. Tumor-targeted immune complex formation: effects on myeloid cell activation and tumor-directed immune cell migration. Int. J. Cancer. 98:2002;857-863.
19. Laemmli U.K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 227:1970;680-685.
20. Li L., Spendlove I., Morgan J., Durrant L.G. CD55 is over-expressed in the tumour environment. Br. J. Cancer. 84:2001;80-86.
21. Marquet R.L., Westbroek D.L., Jeekel J. Interferon treatment of a transplantable rat colon adenocarcinoma: importance of tumor site. Int. J. Cancer. 33:1984;689-692.
22. Maxwell-Armstrong C.A., Durrant L.G., Buckley T.J., Scholefield J.H., Robins R.A., Fielding K., Monson J.R., Guillou P., Calvert H., Carmichael J., Hardcastle J.D. Randomized double-blind phase II survival study comparing immunization with the anti-idiotypic monoclonal antibody 105AD7 against placebo in advanced colorectal cancer. Br. J. Cancer. 84:2001;1443-1446.
23. Mead R., Hinchliffe S.J., Morgan B.P. Molecular cloning, expression and characterization of the rat analogue of human membrane cofactor protein (MCP/CD46). Immunology. 98:1999;137-143.
24. Meri S., Morgan B.P., Davies A., Daniels R.H., Olavesen M.G., Waldmann H., Lachmann P.J. Human protectin (CD59), an 18,000-20,000 MW complement lysis restricting factor, inhibits C5b-8 catalysed insertion of C9 into lipid bilayers. Immunology. 71:1990;1-9.
25. Michaelsen T.E., Garred P., Aase A. Human IgG subclass pattern of inducing complement-mediated cytolysis depends on antigen concentration and to a lesser extent on epitope patchiness, antibody affinity and complement concentration. Eur. J. Immunol. 21:1991;11-16.
26. Miles D.W. Update on HER-2 as a target for cancer therapy: herceptin in the clinical setting. Breast Cancer Res. 3:2001;380-384.
27. Miwa T., Song W.C. Membrane complement regulatory proteins: insight from animal studies and relevance to human diseases. Int. Immunopharmacol. 1:2001;445-459.
28. Miwa T., Nonaka M., Okada N., Wakana S., Shiroishi T., Okada H. Molecular cloning of rat and mouse membrane cofactor protein (MCP, CD46): preferential expression in testis and close linkage between the mouse Mcp and Cr2 genes on distal chromosome 1. Immunogenetics. 48:1998;363-371.
29. Nicholson-Weller A., Wang C. Structure and function of decay accelerating factor CD55. J. Lab. Clin. Med. 123:1994;485-491.
30. Niehans G.A., Cherwitz D.L., Staley N.A., Knapp D.J., Dalmasso A.P. Human carcinomas variably express the complement inhibitory proteins CD46 (membrane cofactor protein), CD55 (decay-accelerating factor), and CD59 (protectin). Am. J. Pathol. 149:1996;129-142.
31. Parham P. On the fragmentation of monoclonal IgG1, IgG2a, and IgG2b from BALB/c mice. J. Immunol. 131:1983;2895-2902.
32. Riethmuller G., Holz E., Schlimok G., Schmiegel W., Raab R., Hoffken K., Gruber R., Funke I., Pichlmaier H., Hirche H., Buggisch P., Witte J., Pichlmayr R. Monoclonal antibody therapy for resected Dukes' C colorectal cancer: 7-year outcome of a multicenter randomized trial. J. Clin. Oncol. 16:1998;1788-1794.
33. Seya T., Turner J.R., Atkinson J.P. Purification and characterization of a membrane protein (gp45-70) that is a cofactor for cleavage of C3b and C4b. J. Exp. Med. 163:1986;837-855.
34. Spiller O.B., Hanna S.M., Morgan B.P. Tissue distribution of the rat analogue of decay-accelerating factor. Immunology. 97:1999;374-384.
35. Takahashi H., Nakada T., Nakaki M., Wands J.R. Inhibition of hepatic metastases of human colon cancer in nude mice by a chimeric SF-25 monoclonal antibody. Gastroenterology. 108:1995;172-182.
36. Takizawa H., Okada N., Okada H. Complement inhibitor of rat cell membrane resembling mouse Crry/p65. J. Immunol. 152:1994;3032-3038.
37. Thorsteinsson L., O'Dowd G.M., Harrington P.M., Johnson P.M. The complement regulatory proteins CD46 and CD59, but not CD55, are highly expressed by glandular epithelium of human breast and colorectal tumour tissues. APMIS. 106:1998;869-878.
38. Van Dijk J., Uemura H., Beniers A.J.M.C., Peelen W.P., Zegveld S.T., Fleuren G.J., Warnaar S.O., Oosterwijk E. Therapeutic effects of monoclonal antibody G250, interferons and tumor necrosis factor, in mice with renal-cell carcinoma xenografts. Int. J. Cancer. 56:1994;262-268.
39. Velders M.P., Van Rhijn C.M., Briaire I.H., Fleuren G.J., Warnaar S.O., Litvinov S.V. Immunotherapy with low and high affinity monoclonal antibodies 17-1A and 323/A3 in a nude mouse xenograft carcinoma model. Cancer Res. 55:1995;4398-4403.
40. Vogt R.F. Jr., Whitfield W.E., Henderson L.O., Hannon W.H. Fluorescence intensity calibration for immunophenotyping by flow cytometry. Methods. 21:2000;289-296.
41. Yamakawa M., Yamada K., Tsuge T., Ohrui H., Ogata T., Dobashi M., Imai Y. Protection of thyroid cancer cells by complement-regulatory factors. Cancer. 73:1994;2808-2817.
42. Yu J., Caragine T., Chen S., Morgan B.P., Frey A.B., Tomlinson S. Protection of human breast cancer cells from complement-mediated lysis by expression of heterologous CD59. Clin. Exp. Immunol. 115:1999;13-18.